Abstract: Impact Therapeutics, a China-based near-commercial-stage biopharma company, is looking to raise at least USD 100 million via a Hong Kong listing. GS and CICC are the joint sponsors. In our previous note, we looked at the company’s core products, senaparib/IMP4297, and key products IMP1734 and IMP9064. We also looked at the company’s pre-IPO investors and management team. In this note, we look at the latest prospectus and analyze changes in the company's pipeline and competitive landscapes.
JIANGSU HENGRUI PHARMACEUTICALS, HANSOH PHARMACEUTICAL, ZAI LAB
Research on Hong Kong and A+H equity offerings, from the first filing to the aftermarket. Coverage includes pre-IPO early thoughts on the business and valuation, analysis of the final deal terms and cornerstone investors, and updates as new prospectus versions are filed.
Interested in the full report? Get in touch with our team.